Trends in Pharmacological Sciences
TIPS reviewAmyloid deposition as the central event in the aetiology of Alzheimer's disease
Abstract
While there may be many causes of Alzheimer's disease (AD), the same pathological sequence of events, described here by John Hardy and David Allsop, is likely to occur in all cases. The recent discovery of a pathogenic mutation in the β-amyloid precursor protein (APP) gene on chromosome 21 suggests that APP mismetabolism and β-amyloid deposition are the primary events in the disease process. The occurrence of AD in Down syndrome is consistent with this hypothesis. The pathological cascade for the disease process is most likely to be: β-amyloid deposition → tau phosphorylation and tangle formation → neuronal death. The development of a biochemical understanding of this pathological cascade will facilitate rational design of drugs to intervene in this process.
References (50)
- H. Yamaguchi et al.
Brain Res.
(1990) - O. Bugiani et al.
Neurosci. Lett.
(1989) - H. Yamaguchi
Brain Res.
(1990) - H. Braak et al.
Neurosci. Lett.
(1986) - Y. Ihara
Brain Res.
(1988) - P.H. St George-Hyslop
Neurobiol. Aging
(1989) - A. Weidemann
Cell
(1989) - M.B. Podlisny
Biochem. Biophys. Res. Commun.
(1990) - G.M. Cole et al.
Biochem. Biophys. Res. Commun.
(1990) - A.I. Bush
J. Biol. Chem.
(1990)
Neurosci. Lett.
Brain Res.
Brain Res.
J. Neurol. Sci.
Neurosci. Lett.
Biochem. Biophys. Res. Commun.
Nature
Nature
Neuropathol. Appl. Neurobiol.
New Engl. J. Med.
J. Neurol. Neurosurg. Psychiat.
Am. J. Pathol.
Nature
Biochim. Biophys. Acta
Cited by (1990)
Recent studies have suggested that ∼ 25% of the brain glycogen is composed of glucosamine (Gln), though its role in maintaining the balance in nervous system is yet to be fully understood. Here, we have reported the synthesis and protective effect of glucosamine conjugated gold nanoparticles (Gln@CA-AuNP) on the oligomeric and fibrillar fraction of hen egg white lysozyme (HEWL). The synthesized Gln@CA-AuNP (∼ 30.1±3.7 nm) was characterized by different spectroscopy and microscopy techniques. The corresponding biophysical studies suggested that Gln@CA-AuNP could effectively inhibit the HEWLO formation and simultaneously, could restrict the nucleation step of protein aggregation. Studies carried out with human neuroblastoma cells (SH-SY5Y) suggested that Gln@CA-AuNP alleviated protein aggregation induced cell death via inhibition of oligomer formation (∼ 2.4 times), reduction of intracellular oxidative stress (∼ 3.6 times) by uplifting the mitochondrial health. The intracellular delivery of Gln was found to modulate cytosolic Parkin oxidation and restrict autophagic neuronal cell death as confirmed by western blot studies. Further, Gln@CA-AuNP has been found to enhance sulfated glycosaminoglycans (sGAGs) production which suggested its role in protecting the extracellular matrix (ECM) during protein aggregation induced toxicity. Also, neuronal synapse of the in vivo Caenorhabditis elegans model could be preserved with the pre-treatment of Gln@CA-AuNP. Overall, we predict that this approach of neuroprotection via simultaneous targeting of early and late aggregates may serve as a better therapeutic strategy for the treatment of neurodegenerative diseases.
Somatostatin and the pathophysiology of Alzheimer's disease
2024, Ageing Research ReviewsAmong the central features of Alzheimer’s disease (AD) progression are altered levels of the neuropeptide somatostatin (SST), and the colocalisation of SST-positive interneurons (SST-INs) with amyloid-β plaques, leading to cell death. In this theoretical review, I propose a molecular model for the pathogenesis of AD based on SST-IN hypofunction and hyperactivity. Namely, hypofunctional and hyperactive SST-INs struggle to control hyperactivity in medial regions in early stages, leading to axonal Aβ production through excessive presynaptic GABAB inhibition, GABAB1a/APP complex downregulation and internalisation. Concomitantly, excessive SST-14 release accumulates near SST-INs in the form of amyloids, which bind to Aβ to form toxic mixed oligomers. This leads to differential SST-IN death through excitotoxicity, further disinhibition, SST deficits, and increased Aβ release, fibrillation and plaque formation. Aβ plaques, hyperactive networks and SST-IN distributions thereby tightly overlap in the brain. Conversely, chronic stimulation of postsynaptic SST2/4 on gulutamatergic neurons by hyperactive SST-INs promotes intense Mitogen-Activated Protein Kinase (MAPK) p38 activity, leading to somatodendritic p-tau staining and apoptosis/neurodegeneration - in agreement with a near complete overlap between p38 and neurofibrillary tangles. This model is suitable to explain some of the principal risk factors and markers of AD progression, including mitochondrial dysfunction, APOE4 genotype, sex-dependent vulnerability, overactive glial cells, dystrophic neurites, synaptic/spine losses, inter alia. Finally, the model can also shed light on qualitative aspects of AD neuropsychology, especially within the domains of spatial and declarative (episodic, semantic) memory, under an overlying pattern of contextual indiscrimination, ensemble instability, interference and generalisation.
Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation
2024, International Journal of Biological MacromoleculesAs a “silent threat,” Alzheimer's disease (AD) is quickly rising to the top of the list of costly and troublesome diseases facing humanity. It is growing to be one of the most troublesome and expensive conditions, with annual health care costs higher than those of cancer and comparable to those of cardiovascular disorders. One of the main pathogenic characteristics of AD is the deficiency of the neurotransmitter acetylcholine (ACh) which plays a vital role in memory, learning, and attention. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) play a crucial role in hydrolyzing ACh. Consequently, a frequent therapy approach for AD is the suppression of AChE and BChE to improve cholinergic neurotransmission and reduce cognitive symptoms. The accumulation of amyloid plaques (Aβ) is a primary factor contributing to neurodegenerative diseases, particularly AD. Glycogen synthase kinase-3β (GSK3-β) is regarded as a pivotal player in the pathophysiology of AD since dysregulation of this kinase affects all major hallmarks of the disease, such as tau phosphorylation, Aβ aggregation, memory, neurogenesis, and synaptic function. One of the most challenging and risky issues in modern medicinal chemistry is the urgent and ongoing need for the study and development of effective therapeutic candidates for the treatment of AD. A significant class of heterocyclic molecules that can target the complex and multifactorial pathogenesis of AD are fused thiophene derivatives. The goal of the current review is to demonstrate the advancements made in fused thiophene derivatives' anti-AD activity. It also covers their mechanisms of action and studies of the structure-activity relationships in addition to the compilation of significant synthetic routes for fused thiophene derivatives with anti-AD potential. This review is intended to stimulate new ideas in the search for more rationale designs of derivatives based on fused thiophene, hoping to be more potent in treating AD.
An immunological puzzle: The adaptive immune system fuels Alzheimer's disease pathology
2024, Brain, Behavior, and ImmunityAlzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by a concerning rise in prevalence. It is projected that the number of affected individuals will reach a staggering 150 million by 2050. While recent advancements in monoclonal antibodies targeting Aβ have shown some clinical effects, there is an urgent need for improved therapies to effectively address the impeding surge of AD patients worldwide. To achieve this, a deeper understanding of the intricate mechanisms underlying the disease is crucial. In recent years, mounting evidence has underscored the vital role of the innate immune system in AD pathology. However, limited findings persist regarding the involvement of the adaptive immune system. Here, we report on the impact of the adaptive immune system on various aspects of AD by using AppNL-G-F mice crossed into a Rag2−/− background lacking mature adaptive immune cells. In addition, to simulate the continuous exposure to various challenges such as infections that is commonly observed in humans, the innate immune system was activated through the repetitive induction of peripheral inflammation. We observed a remarkably improved performance on complex cognitive tasks when a mature adaptive immune system is absent. Notably, this observation is pathologically associated with lower Aβ plaque accumulation, reduced glial activation, and better-preserved neuronal networks in the mice lacking a mature adaptive immune system. Collectively, these findings highlight the detrimental role of the adaptive immune system in AD and underscore the need for effective strategies to modulate it for therapeutic purposes.
Luteoloside inhibits Aβ1–42 fibrillogenesis, disintegrates preformed fibrils, and alleviates amyloid-induced cytotoxicity
2024, Biophysical ChemistryAbnormal aggregation and fibrillogenesis of amyloid-β protein (Aβ) can cause Alzheimerʼs disease (AD). Thus, the discovery of effective drugs that inhibit Aβ fibrillogenesis in the brain is crucial for the treatment of AD. Luteoloside, as one of the polyphenolic compounds, is found to have a certain therapeutic effect on nervous system diseases. However, it remains unknown whether luteoloside is a potential drug for treating AD by modulating Aβ aggregation pathway. In this study, we performed diverse biophysical and biochemical methods to explore the inhibition of luteoloside on Aβ1–42 which is linked to AD. The results demonstrated that luteoloside efficiently prevented amyloid oligomerization and cross-β-sheet formation, reduced the rate of amyloid growth and the length of amyloid fibrils in a dose-dependent manner. Moreover, luteoloside was able to influence aggregation and conformation of Aβ1–42 during different fiber-forming phases, and it could disintegrate already preformed fibrils of Aβ1–42 and convert them into nontoxic aggregates. Furthermore, luteoloside protected cells from amyloid-induced cytotoxicity and hemolysis, and attenuated the level of reactive oxygen species (ROS). The molecular docking study showed that luteoloside interacted with Aβ1–42 mainly via Conventional Hydrogen Bond, Carbon Hydrogen Bond, Pi-Pi T-shaped, Pi-Alkyl and Pi-Anion, thereby possibly preventing it from forming the aggregates. These observations indicate that luteoloside, a natural anti-oxidant molecule, may be applicable as an effective inhibitor of Aβ, and promote further exploration of the therapeutic strategy against AD.
Molecular mechanisms underlying the effect of tooth shortening on memory dysfunction in Wistar male rat
2024, Archives of Oral BiologyWe investigated the effects of molar tooth shortening on the mRNA expression of the AβPP/BACE1, BDNF/TrkB, and Bax/Bcl-2 signaling pathways in the Wistar male rat hippocampal regions.
Four groups (n = 5 per group) of male Wistar rats (control, SRM (shortened right molar), SLM (shortened left molar), and SBM (shortened bilateral molar)) were used. RNA was isolated from the hippocampus and transformed into cDNA. Real-time quantitative PCR was used to evaluate the mRNA expression levels of AβPP, BACE1, Bax, Bcl-2, BDNF, and TrkB.
Differential mRNA expression was observed in rat groups. SBM significantly upregulated the AβPP, BACE1, and Bax mRNA expressions, whereas the expression levels of Bcl-2, BDNF, and TrkB were decreased. SRM and SLM approximately had the same effect on the expression enhancement of AβPP, BACE1, and Bax; however, SRM was more effective than SLM in increasing the expression of these genes.
Symmetrical molar teeth shortening affected the mRNA expression of AβPP and BACE1, which is related to learning and memory dysfunction.